1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points
US sales momentum builds after Department of Defense hospital approvals Humanitarian deployment in Ukraine provides real-world trauma evidence Expansion targeted into EU and UK alongside Asia and Canada Strong cash balance, no debt, and low logistics costs underpin growth potential
Orthocell (ASX:OCC) flags global growth as nerve repair demand builds. Orthocell reports quarterly revenue of $3.2 million, which Non Executive Chairman John Van Der Wielen describes as in line with internal expectations, with a notable March uptick in US sales. Van Der Wielen highlights recent US Department of Defense hospital approvals and regards this as a significant validation of the company’s nerve repair product, REGENERA. He states that more than 100 US hospitals are now trained, and he expects a sharp revenue ramp-up over coming quarters as surgeon adoption increases.
Van Der Wielen points to humanitarian use in Ukraine as a key real-world proof point. Orthocell has shipped hundreds of units for battlefield trauma, and he says surgeons are reporting successful use in operating theatres on injured soldiers. He notes that a leading Ukrainian surgeon is visiting Perth to present clinical experience, which he views as supporting regulatory credibility and further defence-related adoption.
Global expansion remains a core focus. Van Der Wielen says regulatory applications are underway in the EU and UK, with approvals anticipated before year-end, adding to existing markets including Singapore, Hong Kong, Thailand and Canada. He emphasises Orthocell’s strong $48 million cash position, no debt, minimal logistics costs, and views the stock as a de-risked, defensive healthcare exposure.
